ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

GSK Gsk Plc

1,728.50
23.50 (1.38%)
02 May 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Gsk Plc LSE:GSK London Ordinary Share GB00BN7SWP63 ORD 31 1/4P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  23.50 1.38% 1,728.50 1,727.50 1,728.50 1,729.50 1,695.50 1,705.00 6,275,082 16:35:24
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Pharmaceutical Preparations 30.33B 4.93B 1.1970 14.44 71.14B
Gsk Plc is listed in the Pharmaceutical Preparations sector of the London Stock Exchange with ticker GSK. The last closing price for Gsk was 1,705p. Over the last year, Gsk shares have traded in a share price range of 1,302.60p to 1,729.50p.

Gsk currently has 4,117,033,438 shares in issue. The market capitalisation of Gsk is £71.14 billion. Gsk has a price to earnings ratio (PE ratio) of 14.44.

Gsk Share Discussion Threads

Showing 22426 to 22448 of 33150 messages
Chat Pages: Latest  906  905  904  903  902  901  900  899  898  897  896  895  Older
DateSubjectAuthorDiscuss
20/10/2020
11:21
Always good to keep abreast of the competition...


19th Oct'20:-"Pfizer and Moderna pivotal studies on COVID-19 vaccines near enrollment targets"

As of today, Pfizer/BioNTech's 44K-subject Phase 2/3 study evaluating BNT162b2 has enrolled 39,862 participants, 34,601 of which have received the second shot.

As of Friday, October 16, Moderna has enrolled 29,521 participants in its 30K-subject Phase 3 study of mRNA-1273, 24,496 of which have received the second jab.





"Moderna not far behind Pfizer on vaccine emergency authorization"

The U.S. could authorize emergency use of Moderna's (NASDAQ:MRNA) experimental COVID-19 vaccine in December, according to CEO Stéphane Bancel, if the company gets positive interim results in November from a large clinical trial.
The comments suggest Moderna's timetable isn't that far off from Pfizer's (NYSE:PFE), which said last week it expects to seek U.S. authorization of emergency use of its vaccine by late November.

Pfizer, which is working with Germany's BioNTech (NASDAQ:BNTX) has already manufactured "several hundred thousand doses" at its plant in Puurs, Belgium, according to the Daily Mail. The pharma giant hopes to make 100M doses available this year, a figure that will be dwarfed by the 1.3B the company aims to manufacture in 2021.

geckotheglorious
20/10/2020
09:38
Ok thanks arja... waiting waiting then so
bogman1
20/10/2020
07:45
chart shows a clear downtrend and hence not smart to add yet IMO . About 1350 seems to be support level but charts are not an exact science but next best thing to a crystal ball which are too expensive to buy !
arja
19/10/2020
19:35
Just right. Looking to add myself on this. Sub 14 is a ridiculously low price.
bogman1
19/10/2020
15:40
I've been adding today, the S/P will only get better, plus the Divi not bad either.
igoe104
18/10/2020
20:18
I was a couple of hours early with my investment on Thursday, but pleased with the rebound on Friday. With the Pfizer news, pharma stocks should see sharp rises in the coming weeks.
shammytime
18/10/2020
11:07
Lol, that's why your never hear of a rich chartist.
montyhedge
16/10/2020
21:47
Double head n shoulder no dandruff
williamcooper104
16/10/2020
21:31
Old Chinese ploverb say : Man with 2 legs walk faster than man with one....Hard to argue. spud
spud
16/10/2020
20:42
Tea leaves say.............
badtime
16/10/2020
19:50
Chart says 1300.
djb3
16/10/2020
18:02
jade - historical reasons if I may ask? My bearish positions were slightly larger at one time. ;))
alphorn
16/10/2020
17:17
And imo .. will go to 1500 ! Then make a decision
amaretto1
16/10/2020
17:15
It played the chart spot on to 13.75It should carry on riseing from here.
amaretto1
16/10/2020
17:02
GSK is if anything negatively correlated to the Great British Peso Will have a higher GBP cost base which will be less relative to its much larger USD and EUR revenue streams There's a lot of US life science interest in the U.K. which is based on our scientists being cheaper in USD terms and likely to get cheaper
williamcooper104
16/10/2020
16:57
Glaxo is U.K. listed and headquartered - but that's it - not a domestic company
williamcooper104
16/10/2020
16:55
Inflation resilient assets and a good accountant
williamcooper104
16/10/2020
16:39
Porsche, lol, his got a skateboard.
montyhedge
16/10/2020
16:27
Spent it all attempting to keep his ropey Porsche 924 on the road.....spud
spud
16/10/2020
15:33
Lol he has not got one single share. His a dreamer.
montyhedge
16/10/2020
15:32
P1945, can’t understand why you own so many GSK shares ( you said you had many more than me and I own more than £0.5 million worth) and yet you always seem to berate them!
jadeticl3
16/10/2020
15:16
Does it cannibalise current treatment? (Not belittling the positive impact for patients).
alphorn
16/10/2020
15:07
In a normal market, with that rns these would have been 1550p.
montyhedge
Chat Pages: Latest  906  905  904  903  902  901  900  899  898  897  896  895  Older

Your Recent History

Delayed Upgrade Clock